Data Evaluating Tafasitamab with and without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented at ASH 2020

December 7, 2020 10:02 AM

Preliminary safety and efficacy data from Phase 1b firstMIND trial in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) presented today Also presented today: Long-term subgroup analyses from L-MIND study evaluating tafasitamab combined with lenalidomide in patients with relapsed or refractory DLBCL PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / December 7, 2020 / MorphoSys AG (FSE:MOR; Prime Standard...

Read more

Experion Provides Fiscal 2020 Update

December 7, 2020 8:45 AM

VANCOUVER, BC / ACCESSWIRE / December 7, 2020 / Experion Holdings Ltd. (the "Company" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) is pleased to provide an update from the CEO regarding the Company's strategic and operational execution highlights to date for fiscal 2020. Key Comments on our Strategic Execution The last four quarters have been a transformational period for Experion. Early this year, we...

Read more

Apollo Endosurgery Extends Maturity Date on Senior Secured Term Loan and Convertible Notes

December 7, 2020 8:30 AM

AUSTIN, TX / ACCESSWIRE / December 7, 2020 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced an agreement with Solar Capital Ltd. to extend the interest only period and maturity date of its existing term loan. In addition, the Company and holders of 99.25% of the outstanding principal amount of its 6% convertible notes due...

Read more

Edesa Biotech Reports Fiscal Year 2020 Results

December 7, 2020 7:45 AM

TORONTO, ON / ACCESSWIRE / December 7, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the fiscal year ended September 30, 2020 and provided an update on its business. During the fiscal year, Edesa added two Phase 2-ready biologics to its development pipeline, with a focus on COVID-19 and other strategic indications. Last month, the company initiated a Phase 2/Phase 3...

Read more

Lexaria to Highlight its DehydraTECHTM Technology at Four Upcoming Investor Conferences

December 7, 2020 6:45 AM

-Benzinga Global Small Cap Conference on December 8th -LD Micro Main Event on Dec 15th -H.C. Wainwright BioConnect, held on Jan 11-14 -Virtual Biotech Showcase, held on Jan 11-14 KELOWNA, BC / ACCESSWIRE / December 7, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announced today that its Chairman & CEO Chris Bunka is scheduled...

Read more

Tetra Bio-Pharma Provides Update on Market Potential for QIXLEEF(TM)

December 7, 2020 6:30 AM

Tetra Estimates Net Sales reaching $675M USD by 2027 Tetra is evaluating potential commercial partners to launch QIXLEEF™ in USA OTTAWA, ON / ACCESSWIRE / December 7, 2020 /  Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today provided an update on the potential US market for QIXLEEF™, a botanical...

Read more

Helix BioPharma Corp. Closes Private Placement

December 4, 2020 8:30 PM

RICHMOND HILL, ON / ACCESSWIRE / December 4, 2020 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced it has closed a private placement financing for gross proceeds of $1,100,000. The terms of the placement are for the purchase of units...

Read more

Wuhan General Group Financials Update

December 4, 2020 10:20 AM

CAPE TOWN, SA / ACCESSWIRE / December 4, 2020 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce the following update to its shareholders: The Company is pleased to inform its shareholders that with OTCIQ having just granted access to the platform, it has started the process of...

Read more

Havn Life Sciences Partners With Veterans Mental Health Non-Profit, Westwood Institute

December 3, 2020 8:00 AM

Westwood Institute Founder, Dr. Marvin Westwood Will Work With Havn Life's Research Team to Develop Best Practices for Combining Therapy and Psychedelic Interventions for Veterans VANCOUVER, BC / ACCESSWIRE / December 3, 2020 / Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company focused on unlocking human potential using evidence-informed research and developing...

Read more

ContextVision Drives Medical Image Enhancement Innovation

December 2, 2020 3:45 PM

Medical Technology Software Company Celebrates Year of Product Expansion and Internal Growth STOCKHOLM / ACCESSWIRE / December 02, 2020 / ContextVision, a medical technology software company specializing in image analysis and artificial intelligence, announces a progressive year of product innovation and talent acquisition. The company will virtually display its latest advancements in image enhancement as well as introduce new key staff to...

Read more

Aqualung Therapeutics Corp. Publication Supports eNAMPT as Both Biomarker & Therapeutic Target in Prostate Cancer; Prostate Cancer KOL New Addition to Scientific Advisory Board

December 2, 2020 11:45 AM

TUCSON, AZ/ ACCESSWIRE / December 2, 2020 / Aqualung Therapeutics, an early-stage biotech company developing an anti-inflammatory therapeutic platform for patients with serious unchecked inflammatory disease, has published proof of concept studies in EBio Medicine suggesting eNAMPT as a potential biomarker for the severity of invasive Prostate Cancer (PCa), and eNAMPT- neutralization as an effective therapeutic approach to limit PCa invasion and...

Read more

Molecular Partners to Share Clinical Data and Expanding Portfolio Strategy at Virtual R&D Day on December 17, 2020

December 2, 2020 11:45 AM

New data from clinical and preclinical oncology programs to be presented Preliminary Phase 1 data from anti-COVID-19 candidate MP0420 (ensovibep) expected ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / December 2, 2020 / Molecular Partners AG (SWX:MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it will host a virtual R&D Day for...

Read more

EV Biologics Signs Funding Agreement for Biotech Security Token Offering

December 2, 2020 8:00 AM

CHEYENNE, WY / ACCESSWIRE / December 2, 2020 / EV Biologics Corp (OTC PINK:YECO) today announced that it has signed a funding agreement with an investment bank to sponsor the raise of $25-$50 million for research and development via a Security Token Offering "STO" - a worlds' first in Biotech. The Company will start this innovative blockchain funding program starting January 1, 2021 that will fund the research and development...

Read more

Tetra Bio-Pharma Completes Major Milestone for COVID-19 Therapeutic

December 2, 2020 6:30 AM

PATHWAY NOW CLEARED FOR HUMAN TRIALS OTTAWA, ON / ACCESSWIRE / December 2, 2020 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development, today announced it has completed Investigational New Drug (IND) -enabling toxicology, clearing the way for human clinical trials for its novel drug candidate ARDS-003. Acute Respiratory Distress...

Read more

Patriot Scientific Corporation Announces Name Change to "Mosaic ImmunoEngineering Inc.", Stock Symbol Change and Reverse Stock Split

December 1, 2020 4:20 PM

NOVATO, CA / ACCESSWIRE / December 1, 2020 / Patriot Scientific Corporation ("Patriot") (OTC PINK:PTSC) announced today that it has changed its name to "Mosaic ImmunoEngineering Inc.", (the "Company" or "Mosaic") effective immediately. In addition, the Company will change its stock symbol on the OTC Market to "CPMV" as described below and will effect a reverse stock split at a ratio of 1-for-500...

Read more

Rising Biosciences, Inc. Expects to Surpass Milestone Sales Benchmark for 2020

December 1, 2020 1:15 PM

SANDUSKY, OH / ACCESSWIRE / December 1, 2020 / Rising Biosciences, Inc. (OTC PINK:RBII) CEO Arthur Hall reported that the company is expecting to achieve and surpass a milestone sales benchmark in the fiscal year 2020. "We were extraordinarily pleased with our sales results in the third quarter, a second consecutive record quarter for us", said Hall. "We're now poised to hit and break the $1 million sales number for the year!...

Read more

Applied UV Announces U.S. Patent to be Issued for a System to Neutralize Pathogens on Tactile Surfaces, Including Bank ATMs

December 1, 2020 8:30 AM

Sterilumen's patent Application for a UV Light sanitizing solution designed to be retrofitted to Bank ATMs to automatically disinfect surfaces on an ATM machine, including a keyboard, touchscreen, credit card reader between uses has been allowed by the U.S. Patent and Trademark Office MOUNT VERNON, NY / ACCESSWIRE / December 1, 2020 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection...

Read more

Hancock Jaffe Announces One Year Follow-up Data on Tenth VenoValve Patient

December 1, 2020 8:30 AM

Patient Shows Significant Improvement at One Year IRVINE, CA / ACCESSWIRE / December 1, 2020 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health, announced today that the tenth VenoValve patient in HJLI's first-in-human, clinical study has successfully reached the one-year milestone. Patient 10's chronic venous insufficiency ("CVI") has...

Read more

Havn Life Attracts International Drug Science and Policy Expert, Joins UK Policy Reform Group

December 1, 2020 8:00 AM

Havn Life Has Joined the UK-Based Conservative Drug Policy Reform Group (CDPRG), Group Organized to Benefit Drug Policy-Making The Havn Life Advisory Board Adds Mr. King, a Vocal Advocate for Drug Policy Reform and Research VANCOUVER, BC / ACCESSWIRE / December 1, 2020 / Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company focused on unlocking human potential using...

Read more

Lexaria’s Patented Technology Significantly Enhances Oral Delivery of Antiviral Drugs

December 1, 2020 6:30 AM

Demonstrates Improved Delivery of Two Classes of Drugs in Use Against HIV/AIDS and under investigation Against SARS-CoV-2/COVID-19 KELOWNA, BC / ACCESSWIRE / December 1, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announces that its DehydraTECHTM technology significantly improved delivery in study animals of...

Read more